Advancing HFpEF Treatment with Novel MRAs - Episode 14
Challenges With Combining Nonsteroidal MRAs and Treatment Adherence in HFpEF
Panelists address adherence challenges and the need for careful coordination when integrating nonsteroidal MRAs into multifaceted treatment plans.
Panelists discussed that although nonsteroidal mineralocorticoid receptor antagonists such as finerenone offer clear clinical advantages, treatment adherence remains a critical barrier to success. Complex regimens, frequent laboratory monitoring, and adverse effect concerns often hinder consistent use.
They emphasized simplifying care through patient education, digital reminders, and coordinated follow-up. Addressing cost and access issues is equally important to ensuring long-term persistence with therapy.
Panelists concluded that optimizing adherence requires aligning clinical simplicity with patient empowerment. When patients understand their treatment rationale and receive ongoing support, therapy success rates improve significantly.
